1 Study Coverage 1.1 Dendritic Cell and Tumor Cell Cancer Vaccine Product Introduction 1.2 Global Dendritic Cell and Tumor Cell Cancer Vaccine Outlook 2017 VS 2022 VS 2028 1.2.1 Global Dendritic Cell and Tumor Cell Cancer Vaccine Sales in US$ Million for the Year 2017-2028 1.2.2 Global Dendritic Cell and Tumor Cell Cancer Vaccine Sales in Volume for the Year 2017-2028 1.3 United States Dendritic Cell and Tumor Cell Cancer Vaccine Outlook 2017 VS 2022 VS 2028 1.3.1 United States Dendritic Cell and Tumor Cell Cancer Vaccine Sales in US$ Million for the Year 2017-2028 1.3.2 United States Dendritic Cell and Tumor Cell Cancer Vaccine Sales in Volume for the Year 2017-2028 1.4 Dendritic Cell and Tumor Cell Cancer Vaccine Market Size, United States VS Global, 2017 VS 2022 VS 2028 1.4.1 The Market Share of United States Dendritic Cell and Tumor Cell Cancer Vaccine in Global, 2017 VS 2022 VS 2028 1.4.2 The Growth Rate of Dendritic Cell and Tumor Cell Cancer Vaccine Market Size, United States VS Global, 2017 VS 2022 VS 2028 1.5 Dendritic Cell and Tumor Cell Cancer Vaccine Market Dynamics 1.5.1 Dendritic Cell and Tumor Cell Cancer Vaccine Industry Trends 1.5.2 Dendritic Cell and Tumor Cell Cancer Vaccine Market Drivers 1.5.3 Dendritic Cell and Tumor Cell Cancer Vaccine Market Challenges 1.5.4 Dendritic Cell and Tumor Cell Cancer Vaccine Market Restraints 1.6 Study Objectives 1.7 Years Considered 2 Market by Type 2.1 Dendritic Cell and Tumor Cell Cancer Vaccine Market Segment by Type 2.1.1 CD 4 2.1.2 CD 8 2.1.3 HER-2 2.1.4 T-helper cell 2.1.5 Others 2.2 Global Dendritic Cell and Tumor Cell Cancer Vaccine Market Size by Type 2.2.1 Global Dendritic Cell and Tumor Cell Cancer Vaccine Sales in Value, by Type (2017, 2022 & 2028) 2.2.2 Global Dendritic Cell and Tumor Cell Cancer Vaccine Sales in Volume, by Type (2017, 2022 & 2028) 2.2.3 Global Dendritic Cell and Tumor Cell Cancer Vaccine Average Selling Price (ASP) by Type (2017, 2022 & 2028) 2.3 United States Dendritic Cell and Tumor Cell Cancer Vaccine Market Size by Type 2.3.1 United States Dendritic Cell and Tumor Cell Cancer Vaccine Sales in Value, by Type (2017, 2022 & 2028) 2.3.2 United States Dendritic Cell and Tumor Cell Cancer Vaccine Sales in Volume, by Type (2017, 2022 & 2028) 2.3.3 United States Dendritic Cell and Tumor Cell Cancer Vaccine Average Selling Price (ASP) by Type (2017, 2022 & 2028) 3 Market by Application 3.1 Dendritic Cell and Tumor Cell Cancer Vaccine Market Segment by Application 3.1.1 Glioblastoma Cancer 3.1.2 Prostate Cancer 3.1.3 Pancreatic Cancer 3.1.4 Colorectal Cancer 3.1.5 Renal Cancer 3.1.6 Lung Cancer 3.1.7 Others 3.2 Global Dendritic Cell and Tumor Cell Cancer Vaccine Market Size by Application 3.2.1 Global Dendritic Cell and Tumor Cell Cancer Vaccine Sales in Value, by Application (2017, 2022 & 2028) 3.2.2 Global Dendritic Cell and Tumor Cell Cancer Vaccine Sales in Volume, by Application (2017, 2022 & 2028) 3.3.3 Global Dendritic Cell and Tumor Cell Cancer Vaccine Average Selling Price (ASP) by Application (2017, 2022 & 2028) 3.3 United States Dendritic Cell and Tumor Cell Cancer Vaccine Market Size by Application 3.3.1 United States Dendritic Cell and Tumor Cell Cancer Vaccine Sales in Value, by Application (2017, 2022 & 2028) 3.3.2 United States Dendritic Cell and Tumor Cell Cancer Vaccine Sales in Volume, by Application (2017, 2022 & 2028) 3.3.3 United States Dendritic Cell and Tumor Cell Cancer Vaccine Average Selling Price (ASP) by Application (2017, 2022 & 2028) 4 Global Dendritic Cell and Tumor Cell Cancer Vaccine Competitor Landscape by Company 4.1 Global Dendritic Cell and Tumor Cell Cancer Vaccine Market Size by Company 4.1.1 Top Global Dendritic Cell and Tumor Cell Cancer Vaccine Manufacturers Ranked by Revenue (2021) 4.1.2 Global Dendritic Cell and Tumor Cell Cancer Vaccine Revenue by Manufacturer (2017-2022) 4.1.3 Global Dendritic Cell and Tumor Cell Cancer Vaccine Sales by Manufacturer (2017-2022) 4.1.4 Global Dendritic Cell and Tumor Cell Cancer Vaccine Price by Manufacturer (2017-2022) 4.2 Global Dendritic Cell and Tumor Cell Cancer Vaccine Concentration Ratio (CR) 4.2.1 Dendritic Cell and Tumor Cell Cancer Vaccine Market Concentration Ratio (CR) (2017-2022) 4.2.2 Global Top 5 and Top 10 Largest Manufacturers of Dendritic Cell and Tumor Cell Cancer Vaccine in 2021 4.2.3 Global Dendritic Cell and Tumor Cell Cancer Vaccine Market Share by Company Type (Tier 1, Tier 2, and Tier 3) 4.3 Global Dendritic Cell and Tumor Cell Cancer Vaccine Manufacturing Base Distribution, Product Type 4.3.1 Global Dendritic Cell and Tumor Cell Cancer Vaccine Manufacturers, Headquarters and Distribution of Producing Region 4.3.2 Manufacturers Dendritic Cell and Tumor Cell Cancer Vaccine Product Type 4.3.3 Date of International Manufacturers Enter into Dendritic Cell and Tumor Cell Cancer Vaccine Market 4.4 Manufacturers Mergers & Acquisitions, Expansion Plans 4.5 United States Dendritic Cell and Tumor Cell Cancer Vaccine Market Size by Company 4.5.1 Top Dendritic Cell and Tumor Cell Cancer Vaccine Players in United States, Ranked by Revenue (2021) 4.5.2 United States Dendritic Cell and Tumor Cell Cancer Vaccine Revenue by Players (2020, 2021 & 2022) 4.5.3 United States Dendritic Cell and Tumor Cell Cancer Vaccine Sales by Players (2020, 2021 & 2022) 5 Global Dendritic Cell and Tumor Cell Cancer Vaccine Market Size by Region 5.1 Global Dendritic Cell and Tumor Cell Cancer Vaccine Market Size by Region: 2017 VS 2022 VS 2028 5.2 Global Dendritic Cell and Tumor Cell Cancer Vaccine Market Size in Volume by Region (2017-2028) 5.2.1 Global Dendritic Cell and Tumor Cell Cancer Vaccine Sales in Volume by Region: 2017-2022 5.2.2 Global Dendritic Cell and Tumor Cell Cancer Vaccine Sales in Volume Forecast by Region (2023-2028) 5.3 Global Dendritic Cell and Tumor Cell Cancer Vaccine Market Size in Value by Region (2017-2028) 5.3.1 Global Dendritic Cell and Tumor Cell Cancer Vaccine Sales in Value by Region: 2017-2022 5.3.2 Global Dendritic Cell and Tumor Cell Cancer Vaccine Sales in Value by Region: 2023-2028 6 Segment in Region Level & Country Level 6.1 North America 6.1.1 North America Dendritic Cell and Tumor Cell Cancer Vaccine Market Size YoY Growth 2017-2028 6.1.2 North America Dendritic Cell and Tumor Cell Cancer Vaccine Market Facts & Figures by Country (2017, 2022 & 2028) 6.1.3 U.S. 6.1.4 Canada 6.2 Asia-Pacific 6.2.1 Asia-Pacific Dendritic Cell and Tumor Cell Cancer Vaccine Market Size YoY Growth 2017-2028 6.2.2 Asia-Pacific Dendritic Cell and Tumor Cell Cancer Vaccine Market Facts & Figures by Region (2017, 2022 & 2028) 6.2.3 China 6.2.4 Japan 6.2.5 South Korea 6.2.6 India 6.2.7 Australia 6.2.8 Taiwan 6.2.9 Indonesia 6.2.10 Thailand 6.2.11 Malaysia 6.2.12 Philippines 6.3 Europe 6.3.1 Europe Dendritic Cell and Tumor Cell Cancer Vaccine Market Size YoY Growth 2017-2028 6.3.2 Europe Dendritic Cell and Tumor Cell Cancer Vaccine Market Facts & Figures by Country (2017, 2022 & 2028) 6.3.3 Germany 6.3.4 France 6.3.5 U.K. 6.3.6 Italy 6.3.7 Russia 6.4 Latin America 6.4.1 Latin America Dendritic Cell and Tumor Cell Cancer Vaccine Market Size YoY Growth 2017-2028 6.4.2 Latin America Dendritic Cell and Tumor Cell Cancer Vaccine Market Facts & Figures by Country (2017, 2022 & 2028) 6.4.3 Mexico 6.4.4 Brazil 6.4.5 Argentina 6.5 Middle East and Africa 6.5.1 Middle East and Africa Dendritic Cell and Tumor Cell Cancer Vaccine Market Size YoY Growth 2017-2028 6.5.2 Middle East and Africa Dendritic Cell and Tumor Cell Cancer Vaccine Market Facts & Figures by Country (2017, 2022 & 2028) 6.5.3 Turkey 6.5.4 Saudi Arabia 6.5.5 U.A.E 7 Company Profiles 7.1 JW CreaGene 7.1.1 JW CreaGene Corporation Information 7.1.2 JW CreaGene Description and Business Overview 7.1.3 JW CreaGene Dendritic Cell and Tumor Cell Cancer Vaccine Sales, Revenue and Gross Margin (2017-2022) 7.1.4 JW CreaGene Dendritic Cell and Tumor Cell Cancer Vaccine Products Offered 7.1.5 JW CreaGene Recent Development 7.2 Miltenyi Biotec 7.2.1 Miltenyi Biotec Corporation Information 7.2.2 Miltenyi Biotec Description and Business Overview 7.2.3 Miltenyi Biotec Dendritic Cell and Tumor Cell Cancer Vaccine Sales, Revenue and Gross Margin (2017-2022) 7.2.4 Miltenyi Biotec Dendritic Cell and Tumor Cell Cancer Vaccine Products Offered 7.2.5 Miltenyi Biotec Recent Development 7.3 GlaxoSmithKline 7.3.1 GlaxoSmithKline Corporation Information 7.3.2 GlaxoSmithKline Description and Business Overview 7.3.3 GlaxoSmithKline Dendritic Cell and Tumor Cell Cancer Vaccine Sales, Revenue and Gross Margin (2017-2022) 7.3.4 GlaxoSmithKline Dendritic Cell and Tumor Cell Cancer Vaccine Products Offered 7.3.5 GlaxoSmithKline Recent Development 7.4 NorthWest BioTherapeutics 7.4.1 NorthWest BioTherapeutics Corporation Information 7.4.2 NorthWest BioTherapeutics Description and Business Overview 7.4.3 NorthWest BioTherapeutics Dendritic Cell and Tumor Cell Cancer Vaccine Sales, Revenue and Gross Margin (2017-2022) 7.4.4 NorthWest BioTherapeutics Dendritic Cell and Tumor Cell Cancer Vaccine Products Offered 7.4.5 NorthWest BioTherapeutics Recent Development 7.5 ImmunoCellular Therapeutics 7.5.1 ImmunoCellular Therapeutics Corporation Information 7.5.2 ImmunoCellular Therapeutics Description and Business Overview 7.5.3 ImmunoCellular Therapeutics Dendritic Cell and Tumor Cell Cancer Vaccine Sales, Revenue and Gross Margin (2017-2022) 7.5.4 ImmunoCellular Therapeutics Dendritic Cell and Tumor Cell Cancer Vaccine Products Offered 7.5.5 ImmunoCellular Therapeutics Recent Development 7.6 EnoChian Bioscience 7.6.1 EnoChian Bioscience Corporation Information 7.6.2 EnoChian Bioscience Description and Business Overview 7.6.3 EnoChian Bioscience Dendritic Cell and Tumor Cell Cancer Vaccine Sales, Revenue and Gross Margin (2017-2022) 7.6.4 EnoChian Bioscience Dendritic Cell and Tumor Cell Cancer Vaccine Products Offered 7.6.5 EnoChian Bioscience Recent Development 7.7 Medigene 7.7.1 Medigene Corporation Information 7.7.2 Medigene Description and Business Overview 7.7.3 Medigene Dendritic Cell and Tumor Cell Cancer Vaccine Sales, Revenue and Gross Margin (2017-2022) 7.7.4 Medigene Dendritic Cell and Tumor Cell Cancer Vaccine Products Offered 7.7.5 Medigene Recent Development 7.8 Tella Incorporation 7.8.1 Tella Incorporation Corporation Information 7.8.2 Tella Incorporation Description and Business Overview 7.8.3 Tella Incorporation Dendritic Cell and Tumor Cell Cancer Vaccine Sales, Revenue and Gross Margin (2017-2022) 7.8.4 Tella Incorporation Dendritic Cell and Tumor Cell Cancer Vaccine Products Offered 7.8.5 Tella Incorporation Recent Development 8 Industry Chain and Sales Channels Analysis 8.1 Dendritic Cell and Tumor Cell Cancer Vaccine Industry Chain Analysis 8.2 Dendritic Cell and Tumor Cell Cancer Vaccine Key Raw Materials 8.2.1 Key Raw Materials 8.2.2 Dendritic Cell and Tumor Cell Cancer Vaccine Distributors 8.3 Dendritic Cell and Tumor Cell Cancer Vaccine Production Mode & Process 8.4 Dendritic Cell and Tumor Cell Cancer Vaccine Sales and Marketing 8.4.1 Dendritic Cell and Tumor Cell Cancer Vaccine Sales Channels 8.4.2 Dendritic Cell and Tumor Cell Cancer Vaccine Distributors 8.5 Dendritic Cell and Tumor Cell Cancer Vaccine Customers 9 Research Findings and Conclusion 10 Appendix 10.1 Research Methodology 10.1.1 Methodology/Research Approach 10.1.2 Data Source 10.2 Author Details 10.3 Disclaimer

List of Tables Table 1. Dendritic Cell and Tumor Cell Cancer Vaccine CAGR in Value, United States VS Global, 2017 VS 2022 VS 2028 Table 2. Dendritic Cell and Tumor Cell Cancer Vaccine Market Trends Table 3. Dendritic Cell and Tumor Cell Cancer Vaccine Market Drivers Table 4. Dendritic Cell and Tumor Cell Cancer Vaccine Market Challenges Table 5. Dendritic Cell and Tumor Cell Cancer Vaccine Market Restraints Table 6. Global Dendritic Cell and Tumor Cell Cancer Vaccine Sales by Type: 2017 VS 2022 VS 2028 (US$ Million) Table 7. United States Dendritic Cell and Tumor Cell Cancer Vaccine Sales by Type: 2017 VS 2022 VS 2028 (US$ Million) Table 8. Global Dendritic Cell and Tumor Cell Cancer Vaccine Sales by Application: 2017 VS 2022 VS 2028 (US$ Million) Table 9. United States Dendritic Cell and Tumor Cell Cancer Vaccine Sales by Application: 2017 VS 2022 VS 2028 (US$ Million) Table 10. Top Dendritic Cell and Tumor Cell Cancer Vaccine Manufacturers in Global Market, Ranking by Revenue (2021) Table 11. Global Dendritic Cell and Tumor Cell Cancer Vaccine Revenue by Manufacturer, (US$ Million), 2017-2022 Table 12. Global Dendritic Cell and Tumor Cell Cancer Vaccine Revenue Share by Manufacturer, 2017-2022 Table 13. Global Dendritic Cell and Tumor Cell Cancer Vaccine Sales by Manufacturer, (K Units), 2017-2022 Table 14. Global Dendritic Cell and Tumor Cell Cancer Vaccine Sales Share by Manufacturer, 2017-2022 Table 15. Global Dendritic Cell and Tumor Cell Cancer Vaccine Price by Manufacturer (2017-2022) & (USD/Unit) Table 16. Global Dendritic Cell and Tumor Cell Cancer Vaccine Manufacturers Market Concentration Ratio (CR5 and HHI) Table 17. Global Dendritic Cell and Tumor Cell Cancer Vaccine by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Dendritic Cell and Tumor Cell Cancer Vaccine as of 2021) Table 18. Top Players of Dendritic Cell and Tumor Cell Cancer Vaccine in Global Market, Headquarters and Distribution of Producing Region Table 19. Manufacturers Dendritic Cell and Tumor Cell Cancer Vaccine Product Type Table 20. Date of International Manufacturers Enter into Dendritic Cell and Tumor Cell Cancer Vaccine Market Table 21. Manufacturers Mergers & Acquisitions, Expansion Plans Table 22. Top Dendritic Cell and Tumor Cell Cancer Vaccine Players in United States Market, Ranking by Revenue (2021) Table 23. United States Dendritic Cell and Tumor Cell Cancer Vaccine Revenue by Players, (US$ Million), 2020, 2021 & 2022 Table 24. United States Dendritic Cell and Tumor Cell Cancer Vaccine Revenue Share by Players, 2020, 2021 & 2022 Table 25. United States Dendritic Cell and Tumor Cell Cancer Vaccine Sales by Players, (K Units), 2020, 2021 & 2022 Table 26. United States Dendritic Cell and Tumor Cell Cancer Vaccine Sales Share by Players, 2020, 2021 & 2022 Table 27. Global Dendritic Cell and Tumor Cell Cancer Vaccine Market Size by Region (US$ Million): 2017 VS 2022 VS 2028 Table 28. Global Dendritic Cell and Tumor Cell Cancer Vaccine Sales in Volume by Region (2017-2022) & (K Units) Table 29. Global Dendritic Cell and Tumor Cell Cancer Vaccine Sales in Volume Forecast by Region (2023-2028) & (K Units) Table 30. Global Dendritic Cell and Tumor Cell Cancer Vaccine Sales in Value by Region (2017-2022) & (US$ Million) Table 31. Global Dendritic Cell and Tumor Cell Cancer Vaccine Sales in Value Forecast by Region (2023-2028) & (US$ Million) Table 32. North America Dendritic Cell and Tumor Cell Cancer Vaccine Sales in Volume by Country (2017-2028) & (K Units) Table 33. North America Dendritic Cell and Tumor Cell Cancer Vaccine Sales in Value by Country (2017-2028) & (US$ Million) Table 34. Asia Pacific Dendritic Cell and Tumor Cell Cancer Vaccine Sales in Volume by Region (2017-2028) & (K Units) Table 35. Asia Pacific Dendritic Cell and Tumor Cell Cancer Vaccine Sales in Value by Region (2017-2028) & (US$ Million) Table 36. Europe Dendritic Cell and Tumor Cell Cancer Vaccine Sales in Volume by Country (2017-2028) & (K Units) Table 37. Europe Dendritic Cell and Tumor Cell Cancer Vaccine Sales in Value by Country (2017-2028) & (US$ Million) Table 38. Latin America Dendritic Cell and Tumor Cell Cancer Vaccine Sales in Volume by Country (2017-2028) & (K Units) Table 39. Latin Americaa Dendritic Cell and Tumor Cell Cancer Vaccine Sales in Value by Country (2017-2028) & (US$ Million) Table 40. Middle East and Africa Dendritic Cell and Tumor Cell Cancer Vaccine Sales in Volume by Country (2017-2028) & (K Units) Table 41. Middle East and Africa Dendritic Cell and Tumor Cell Cancer Vaccine Sales in Value by Country (2017-2028) & (US$ Million) Table 42. JW CreaGene Corporation Information Table 43. JW CreaGene Description and Business Overview Table 44. JW CreaGene Dendritic Cell and Tumor Cell Cancer Vaccine Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022) Table 45. JW CreaGene Dendritic Cell and Tumor Cell Cancer Vaccine Product Table 46. JW CreaGene Recent Development Table 47. Miltenyi Biotec Corporation Information Table 48. Miltenyi Biotec Description and Business Overview Table 49. Miltenyi Biotec Dendritic Cell and Tumor Cell Cancer Vaccine Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022) Table 50. Miltenyi Biotec Product Table 51. Miltenyi Biotec Recent Development Table 52. GlaxoSmithKline Corporation Information Table 53. GlaxoSmithKline Description and Business Overview Table 54. GlaxoSmithKline Dendritic Cell and Tumor Cell Cancer Vaccine Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022) Table 55. GlaxoSmithKline Product Table 56. GlaxoSmithKline Recent Development Table 57. NorthWest BioTherapeutics Corporation Information Table 58. NorthWest BioTherapeutics Description and Business Overview Table 59. NorthWest BioTherapeutics Dendritic Cell and Tumor Cell Cancer Vaccine Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022) Table 60. NorthWest BioTherapeutics Product Table 61. NorthWest BioTherapeutics Recent Development Table 62. ImmunoCellular Therapeutics Corporation Information Table 63. ImmunoCellular Therapeutics Description and Business Overview Table 64. ImmunoCellular Therapeutics Dendritic Cell and Tumor Cell Cancer Vaccine Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022) Table 65. ImmunoCellular Therapeutics Product Table 66. ImmunoCellular Therapeutics Recent Development Table 67. EnoChian Bioscience Corporation Information Table 68. EnoChian Bioscience Description and Business Overview Table 69. EnoChian Bioscience Dendritic Cell and Tumor Cell Cancer Vaccine Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022) Table 70. EnoChian Bioscience Product Table 71. EnoChian Bioscience Recent Development Table 72. Medigene Corporation Information Table 73. Medigene Description and Business Overview Table 74. Medigene Dendritic Cell and Tumor Cell Cancer Vaccine Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022) Table 75. Medigene Product Table 76. Medigene Recent Development Table 77. Tella Incorporation Corporation Information Table 78. Tella Incorporation Description and Business Overview Table 79. Tella Incorporation Dendritic Cell and Tumor Cell Cancer Vaccine Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022) Table 80. Tella Incorporation Product Table 81. Tella Incorporation Recent Development Table 82. Key Raw Materials Lists Table 83. Raw Materials Key Suppliers Lists Table 84. Dendritic Cell and Tumor Cell Cancer Vaccine Customers List Table 85. Dendritic Cell and Tumor Cell Cancer Vaccine Distributors List Table 86. Research Programs/Design for This Report Table 87. Key Data Information from Secondary Sources Table 88. Key Data Information from Primary Sources List of Figures Figure 1. Dendritic Cell and Tumor Cell Cancer Vaccine Product Picture Figure 2. Global Dendritic Cell and Tumor Cell Cancer Vaccine Revenue, (US$ Million), 2017 VS 2022 VS 2028 Figure 3. Global Dendritic Cell and Tumor Cell Cancer Vaccine Market Size 2017-2028 (US$ Million) Figure 4. Global Dendritic Cell and Tumor Cell Cancer Vaccine Sales 2017-2028 (K Units) Figure 5. United States Dendritic Cell and Tumor Cell Cancer Vaccine Revenue, (US$ Million), 2017 VS 2022 VS 2028 Figure 6. United States Dendritic Cell and Tumor Cell Cancer Vaccine Market Size 2017-2028 (US$ Million) Figure 7. United States Dendritic Cell and Tumor Cell Cancer Vaccine Sales 2017-2028 (K Units) Figure 8. United States Dendritic Cell and Tumor Cell Cancer Vaccine Market Share in Global, in Value (US$ Million) 2017-2028 Figure 9. United States Dendritic Cell and Tumor Cell Cancer Vaccine Market Share in Global, in Volume (K Units) 2017-2028 Figure 10. Dendritic Cell and Tumor Cell Cancer Vaccine Report Years Considered Figure 11. Product Picture of CD 4 Figure 12. Product Picture of CD 8 Figure 13. Product Picture of HER-2 Figure 14. Product Picture of T-helper cell Figure 15. Product Picture of Others Figure 16. Global Dendritic Cell and Tumor Cell Cancer Vaccine Market Share by Type in 2022 & 2028 Figure 17. Global Dendritic Cell and Tumor Cell Cancer Vaccine Sales in Value by Type (2017-2028) & (US$ Million) Figure 18. Global Dendritic Cell and Tumor Cell Cancer Vaccine Sales Market Share in Value by Type (2017-2028) Figure 19. Global Dendritic Cell and Tumor Cell Cancer Vaccine Sales by Type (2017-2028) & (K Units) Figure 20. Global Dendritic Cell and Tumor Cell Cancer Vaccine Sales Market Share in Volume by Type (2017-2028) Figure 21. Global Dendritic Cell and Tumor Cell Cancer Vaccine Price by Type (2017-2028) & (USD/Unit) Figure 22. United States Dendritic Cell and Tumor Cell Cancer Vaccine Market Share by Type in 2022 & 2028 Figure 23. United States Dendritic Cell and Tumor Cell Cancer Vaccine Sales in Value by Type (2017-2028) & (US$ Million) Figure 24. United States Dendritic Cell and Tumor Cell Cancer Vaccine Sales Market Share in Value by Type (2017-2028) Figure 25. United States Dendritic Cell and Tumor Cell Cancer Vaccine Sales by Type (2017-2028) & (K Units) Figure 26. United States Dendritic Cell and Tumor Cell Cancer Vaccine Sales Market Share in Volume by Type (2017-2028) Figure 27. United States Dendritic Cell and Tumor Cell Cancer Vaccine Price by Type (2017-2028) & (USD/Unit) Figure 28. Product Picture of Glioblastoma Cancer Figure 29. Product Picture of Prostate Cancer Figure 30. Product Picture of Pancreatic Cancer Figure 31. Product Picture of Colorectal Cancer Figure 32. Product Picture of Renal Cancer Figure 33. Product Picture of Lung Cancer Figure 34. Product Picture of Others Figure 35. Global Dendritic Cell and Tumor Cell Cancer Vaccine Market Share by Application in 2022 & 2028 Figure 36. Global Dendritic Cell and Tumor Cell Cancer Vaccine Sales in Value by Application (2017-2028) & (US$ Million) Figure 37. Global Dendritic Cell and Tumor Cell Cancer Vaccine Sales Market Share in Value by Application (2017-2028) Figure 38. Global Dendritic Cell and Tumor Cell Cancer Vaccine Sales by Application (2017-2028) & (K Units) Figure 39. Global Dendritic Cell and Tumor Cell Cancer Vaccine Sales Market Share in Volume by Application (2017-2028) Figure 40. Global Dendritic Cell and Tumor Cell Cancer Vaccine Price by Application (2017-2028) & (USD/Unit) Figure 41. United States Dendritic Cell and Tumor Cell Cancer Vaccine Market Share by Application in 2022 & 2028 Figure 42. United States Dendritic Cell and Tumor Cell Cancer Vaccine Sales in Value by Application (2017-2028) & (US$ Million) Figure 43. United States Dendritic Cell and Tumor Cell Cancer Vaccine Sales Market Share in Value by Application (2017-2028) Figure 44. United States Dendritic Cell and Tumor Cell Cancer Vaccine Sales by Application (2017-2028) & (K Units) Figure 45. United States Dendritic Cell and Tumor Cell Cancer Vaccine Sales Market Share in Volume by Application (2017-2028) Figure 46. United States Dendritic Cell and Tumor Cell Cancer Vaccine Price by Application (2017-2028) & (USD/Unit) Figure 47. North America Dendritic Cell and Tumor Cell Cancer Vaccine Sales in Volume Growth Rate 2017-2028 (K Units) Figure 48. North America Dendritic Cell and Tumor Cell Cancer Vaccine Sales in Value Growth Rate 2017-2028 (US$ Million) Figure 49. U.S. Dendritic Cell and Tumor Cell Cancer Vaccine Sales in Value Growth Rate (2017-2028) & (US$ Million) Figure 50. Canada Dendritic Cell and Tumor Cell Cancer Vaccine Sales in Value Growth Rate (2017-2028) & (US$ Million) Figure 51. Europe Dendritic Cell and Tumor Cell Cancer Vaccine Sales in Volume Growth Rate 2017-2028 (K Units) Figure 52. Europe Dendritic Cell and Tumor Cell Cancer Vaccine Sales in Value Growth Rate 2017-2028 (US$ Million) Figure 53. Germany Dendritic Cell and Tumor Cell Cancer Vaccine Sales in Value Growth Rate (2017-2028) & (US$ Million) Figure 54. France Dendritic Cell and Tumor Cell Cancer Vaccine Sales in Value Growth Rate (2017-2028) & (US$ Million) Figure 55. U.K. Dendritic Cell and Tumor Cell Cancer Vaccine Sales in Value Growth Rate (2017-2028) & (US$ Million) Figure 56. Italy Dendritic Cell and Tumor Cell Cancer Vaccine Sales in Value Growth Rate (2017-2028) & (US$ Million) Figure 57. Russia Dendritic Cell and Tumor Cell Cancer Vaccine Sales in Value Growth Rate (2017-2028) & (US$ Million) Figure 58. Asia-Pacific Dendritic Cell and Tumor Cell Cancer Vaccine Sales in Volume Growth Rate 2017-2028 (K Units) Figure 59. Asia-Pacific Dendritic Cell and Tumor Cell Cancer Vaccine Sales in Value Growth Rate 2017-2028 (US$ Million) Figure 60. China Dendritic Cell and Tumor Cell Cancer Vaccine Sales in Value Growth Rate (2017-2028) & (US$ Million) Figure 61. Japan Dendritic Cell and Tumor Cell Cancer Vaccine Sales in Value Growth Rate (2017-2028) & (US$ Million) Figure 62. South Korea Dendritic Cell and Tumor Cell Cancer Vaccine Sales in Value Growth Rate (2017-2028) & (US$ Million) Figure 63. India Dendritic Cell and Tumor Cell Cancer Vaccine Sales in Value Growth Rate (2017-2028) & (US$ Million) Figure 64. Australia Dendritic Cell and Tumor Cell Cancer Vaccine Sales in Value Growth Rate (2017-2028) & (US$ Million) Figure 65. Taiwan Dendritic Cell and Tumor Cell Cancer Vaccine Sales in Value Growth Rate (2017-2028) & (US$ Million) Figure 66. Indonesia Dendritic Cell and Tumor Cell Cancer Vaccine Sales in Value Growth Rate (2017-2028) & (US$ Million) Figure 67. Thailand Dendritic Cell and Tumor Cell Cancer Vaccine Sales in Value Growth Rate (2017-2028) & (US$ Million) Figure 68. Malaysia Dendritic Cell and Tumor Cell Cancer Vaccine Sales in Value Growth Rate (2017-2028) & (US$ Million) Figure 69. Philippines Dendritic Cell and Tumor Cell Cancer Vaccine Sales in Value Growth Rate (2017-2028) & (US$ Million) Figure 70. Latin America Dendritic Cell and Tumor Cell Cancer Vaccine Sales in Volume Growth Rate 2017-2028 (K Units) Figure 71. Latin America Dendritic Cell and Tumor Cell Cancer Vaccine Sales in Value Growth Rate 2017-2028 (US$ Million) Figure 72. Mexico Dendritic Cell and Tumor Cell Cancer Vaccine Sales in Value Growth Rate (2017-2028) & (US$ Million) Figure 73. Brazil Dendritic Cell and Tumor Cell Cancer Vaccine Sales in Value Growth Rate (2017-2028) & (US$ Million) Figure 74. Argentina Dendritic Cell and Tumor Cell Cancer Vaccine Sales in Value Growth Rate (2017-2028) & (US$ Million) Figure 75. Middle East & Africa Dendritic Cell and Tumor Cell Cancer Vaccine Sales in Volume Growth Rate 2017-2028 (K Units) Figure 76. Middle East & Africa Dendritic Cell and Tumor Cell Cancer Vaccine Sales in Value Growth Rate 2017-2028 (US$ Million) Figure 77. Turkey Dendritic Cell and Tumor Cell Cancer Vaccine Sales in Value Growth Rate (2017-2028) & (US$ Million) Figure 78. Saudi Arabia Dendritic Cell and Tumor Cell Cancer Vaccine Sales in Value Growth Rate (2017-2028) & (US$ Million) Figure 79. U.A.E Dendritic Cell and Tumor Cell Cancer Vaccine Sales in Value Growth Rate (2017-2028) & (US$ Million) Figure 80. Dendritic Cell and Tumor Cell Cancer Vaccine Value Chain Figure 81. Dendritic Cell and Tumor Cell Cancer Vaccine Production Process Figure 82. Channels of Distribution Figure 83. Distributors Profiles Figure 84. Bottom-up and Top-down Approaches for This Report Figure 85. Data Triangulation Figure 86. Key Executives Interviewed

JW CreaGene Miltenyi Biotec GlaxoSmithKline NorthWest BioTherapeutics ImmunoCellular Therapeutics EnoChian Bioscience Medigene Tella Incorporation